文献速递消化系统肿瘤

局部晚期直肠癌全程新辅助治疗:FOLFOXIRI联合贝伐珠单抗序贯放化疗联合贝伐珠单抗的TRUST试验

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
PubMed 文献 · Eur J Cancer · 2019-02-07

TRUST为II期单臂试验,纳入49例淋巴结阳性或cT4或高危cT3局部晚期直肠癌患者,接受6周期FOLFOXIRI联合贝伐珠单抗诱导,序贯50.4 Gy放疗联合卡培他滨及贝伐珠单抗,主要终点2年无病生存率达80.45%(95%CI 78.79-82.10),达到主要终点,方案可行且活跃。

要点

  • 2年无病生存率80.45%(95%CI 78.79-82.10),研究达到主要终点。
  • 44例接受手术,病理完全缓解率36.4%。
  • 诱导期主要G3/4毒性为中性粒细胞减少(41.6%)和腹泻(12.5%)。

核心结论

  • FOLFOXIRI联合贝伐珠单抗序贯放化疗联合贝伐珠单抗方案可行且活跃,无病生存结果提示该策略可能改善局部晚期直肠癌的远处疾病控制。

研究设计与样本

  • II期单臂试验,纳入淋巴结阳性或临床T4或高危T3局部晚期直肠癌患者,共入组49例,除1例入组后撤回知情同意外均纳入符合方案分析。
  • 患者接受6周期FOLFOXIRI联合贝伐珠单抗诱导化疗,序贯放疗50.4 Gy联合卡培他滨及贝伐珠单抗(第1、15、28天5 mg/kg),放疗完成后8周计划手术。
  • 主要终点为2年无病生存率。

主要发现

  • 研究达到主要终点:36例患者2年时无复发,2年无病生存率80.45%(95%CI 78.79-82.10)。
  • 44例患者接受手术,病理完全缓解率36.4%。
  • 46例完成诱导化疗,主要G3/4毒性为中性粒细胞减少(41.6%)和腹泻(12.5%)。
  • 45例接受放化疗,因G3手足综合征和直肠炎发生率23.1%,方案修正后对13例之后患者的卡培他滨给药方案略作调整,修正后放化疗期间未报告严重事件。

关键数值与推荐

  • 2年无病生存率80.45%(95%CI 78.79-82.10)。
  • 病理完全缓解率36.4%。
  • 诱导化疗G3/4中性粒细胞减少发生率41.6%,腹泻发生率12.5%。
  • 放化疗期间G3手足综合征和直肠炎发生率23.1%。
  • 贝伐珠单抗在放化疗期间剂量为5 mg/kg,第1、15、28天给药;放疗剂量50.4 Gy。

临床怎么用

  • 原文结论认为该全程新辅助治疗策略可行且活跃,无病生存结果提示可能改善局部晚期直肠癌的远处疾病控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) does not achieve effective control of distant metastases. Induction chemotherapy is a promising strategy, and bevacizumab (BV) could improve the results of CRT. 5-Fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) plus BV is a treatment option in metastatic colorectal cancer. We evaluate feasibility and efficacy of neoadjuvant treatment comprising induction FOLFOXIRI plus BV followed by CRT with fluoropyrimidines plus BV. METHODS: In this phase II single-arm trial, patients node-positive or clinical T4 or high-risk T3 LARC underwent 6 cycles of induction FOLFOXIRI plus BV, followed by CRT (50.4 Gy plus concomitant capecitabine) and BV (5 mg/kg on days 1, 15 and 28). Surgery was planned 8 weeks after completion of CRT. Primary end-point was 2-year disease-free survival (DFS). RESULTS: We enrolled 49 patients: All but one (withdrewing consent after enrolment) were included in the per-protocol analyses. The study met its primary end-point: 36 patients were free of recurrence at 2 years (2-y DFS: 80.45%, 95% confidence interval [CI]: 78.79-82.10). Forty-four patients underwent surgery; pathologic complete response rate was 36.4%. Forty-six patients completed induction: neutropenia (41.6%) and diarrhoea (12.5%) were main G3/4 toxicities. Forty-five patients received CRT, but the protocol was amended and the capecitabine schedule during CRT was slightly modified after 13 patients due to the incidence of G3 hand-foot syndrome and proctitis (23.1%). After amendment, no severe events during CRT were reported. CONCLUSIONS: FOLFOXIRI plus BV followed by CRT plus BV is feasible and active. Results in terms of DFS suggest that this strategy may improve distant disease control in LARC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Masi G, Vivaldi C, Fornaro L, et al. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Eur J Cancer. 2019. PMID: 30739838. doi:10.1016/j.ejca.2019.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。